Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023
Vabysmo data suggest rapid and robust drying of retinal fluid in patients withneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaReal-world studies ofVabysmo demonstrate ability to extend treatment intervals in the first four months while maintaining visual acuityClinical data on an investigational anti-interleukin-6 treatment inuveitic macular edema will be presented for the first timeBasel, 13 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association for Research ...
Source: Roche Media News - April 13, 2023 Category: Pharmaceuticals Source Type: news
Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
Roche and Lilly will collaborate on the development of Roche Diagnostics ’Elecsys Amyloid Plasma PanelTheElecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validationOnce approved, could help healthcare professionals to streamline the journey to diagnosis for more patientsBasel, 22 March, 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a collaboration with Eli Lilly and Company to support the development of Roche ’s Elecsys® Amyloid Plasma Panel (EAPP). The EAPP is an innovative blood test that ai...
Source: Roche Media News - March 22, 2023 Category: Pharmaceuticals Source Type: news
New four year data for Roche ’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decreaseData confirm long-term efficacy and safety profile ofEvrysdi in a broad range of people with Type 2 and non‑ambulant Type 3 SMAMore than 8,500 people —from newborns to the over 60s—have been treated withEvrysdi, which is now approved in more than 90 countries worldwideBasel, 20 March 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data for Evrysdi ® (risdiplam) in a broad range of people aged 2-...
Source: Roche Media News - March 20, 2023 Category: Pharmaceuticals Source Type: news
Roche Annual General Meeting 2023
All proposals of the Board of Directors approvedSeverin Schwan elected as new Chairman of the Board of Directors; all other members of the Board of Directors standing for election were electedThomasSchinecker new Roche Group CEO as of today36th dividend increase in succession to CHF9.50 per shareand non-voting equity securityBasel, 14 March 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the ordinary Annual General Meeting has elected Severin Schwan as the new Chairman of the Board of Directors with 98.32% of the votes and has approved all of the Board ' s proposals. The 574 shareholders present, who represe...
Source: Roche Media News - March 14, 2023 Category: Pharmaceuticals Source Type: news
FDA Advisory Committee votes in favour of the clinical benefit of Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
U.S. FDA ’s Oncologic Drugs Advisory Committee voted 11 to 2 in favour of the clinical benefit of the phase III POLARIX study of Polivy in combination with R-CHP for people with previously untreated diffuse large B-cell lymphoma (DLBCL)This is the first treatment in 20 years to show a significant and clinically meaningful improvement in progression-free survival over the standard of care for first-line DLBCLDLBCL is an aggressive, hard-to-treat disease and the most common form of non-Hodgkin lymphoma in the USBasel, 10 March 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administrat...
Source: Roche Media News - March 10, 2023 Category: Pharmaceuticals Source Type: news
Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
Recent advances in cancer genomics have deepened the medical community ’s understanding of the molecular alterations in braintumours, more preciselysubclassifying patients into specific diagnoses.Understanding a patient ' sbraintumour mutation status in the IDH1 and ATRX genes enables more informed clinical decisions and may improve patient outcomes.The IDH1 R132H and ATRX antibodies are the latest additions to Roche ’s neuropathology portfolio, which contains 29 biomarkers.Basel, 23 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibo...
Source: Roche Media News - February 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares
Basel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Roche Long Term Foundation acquired 540 ’000 Roche bearer shares at the price determined via an accelerated book building (ABB) process. The Foundation will use these shares to cover current as well as future obligations arising from equity compensation plans. This announcement is based on reports that a member of a shareholder group wi th pooled voting rights sold 2.7 million Roche bearer shares via this ABB process. Following this transaction, the shareholder group with pooled voting rights owns circa 65% (previously 67.5%) of the iss...
Source: Roche Media News - February 10, 2023 Category: Pharmaceuticals Source Type: news
New phase III data show Roche ’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared toafliberceptMoreVabysmo patients showed an absence of blood vessel leakage in the retina compared toaflibercept in a pre-specified exploratory endpointIf approved, RVO would be the third indication forVabysmo in addition toneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaBasel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo ® (faricimab) in macular ...
Source: Roche Media News - February 10, 2023 Category: Pharmaceuticals Source Type: news
Roche announces donation of essential medicines and diagnostic solutions to the people affected by the devastating earthquake in T ürkiye and Syria
Basel, 9 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a donation to T ürkiye and Syria with a total value of 1.5 million Swiss Francs. This includes medicines, other products and financial support. Among others, we are committed to donating 120,000 packages of Rocephin, a critical antibiotic used to treat the symptoms of many kinds of bacterial infections and listed on the World Health Organization’s list of essential medicines. In addition we are committed to donating much needed supplies for diabetes management.Roche is deeply saddened by the devastating earthquake in T ürkiye and Syria on Febru...
Source: Roche Media News - February 9, 2023 Category: Pharmaceuticals Source Type: news
Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition
The COMMODORE 2 study met its co-primary efficacy endpoints, showingcrovalimab achieved disease control in people with paroxysmal nocturnalhaemoglobinuria (PNH) who have not been previously treated with complement inhibitorsThe results of the phase III COMMODORE 1 study in people with PNH switching from currently approved C5 inhibitors, supported thefavourable benefit-risk profile ofcrovalimab, as seen in the pivotal COMMODORE 2 studyResults from both studies will be submitted to regulatory authorities around the world and presented at an upcoming medical meetingBasel, 7 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) t...
Source: Roche Media News - February 7, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche ’s Corporate Executive Committee
Basel, 2 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Board of Directors has made the following appointments:Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO Roche Pharmaceuticals based in Basel, Switzerland effective March 2023 and will become a member of the Corporate Executive Committee. At the same time, Levi Garraway, Chief Medical Officer and Executive Vice President, Global Product Development, based in South San Francisco, will become a member of the enlarged Corporate Executive Committee. Both will report to the Roche Group CE...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves label expansion of Roche ’s Hemlibra to include people with moderate haemophilia A in the EU
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia A can have a significant impact on the lives of people affected, with only 15% living a bleed-free life1The approval is based on the HAVEN 6 results, whereHemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors2Basel, 01 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission approved the expansion of the He...
Source: Roche Media News - February 1, 2023 Category: Pharmaceuticals Source Type: news
Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platformsLightCycler® 480 II* andcobas® z480.Results from the test will help closely track the virus ’ lineage and provide insights into the epidemiology and impact it has on public health.Concern from the World HealthOrganisationcentres around the XBB.1.5 high transmissibility and growth advantage.1Basel, 26 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5...
Source: Roche Media News - January 26, 2023 Category: Pharmaceuticals Source Type: news
